Publications

Found 1 results
Filters: Author is H.-T. Zhang  [Clear All Filters]
2012
H. - T. Zhang, Xu, Y., Zhang, Z. - H., and Li, L., Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer, vol. 11, pp. 1642-1650, 2012.
Balistreri CR, Caruso C, Carruba G, Miceli V, et al. (2010). A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr. Pharm. Des. 16: 718-724. http://dx.doi.org/10.2174/138161210790883877 PMid:20388081 Cao H, Xu Z, Long H, Li XQ, et al. (2010). The -765C allele of the cyclooxygenase-2 gene as a potential risk factor of colorectal cancer: a meta-analysis. Tohoku J. Exp. Med. 222: 15-21. http://dx.doi.org/10.1620/tjem.222.15 PMid:20808059 Cheng I, Liu X, Plummer SJ, Krumroy LM, et al. (2007). COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br. J. Cancer 97: 557-561. http://dx.doi.org/10.1038/sj.bjc.6603874 PMid:17609663 PMCid:2360347 Danforth KN, Hayes RB, Rodriguez C, Yu K, et al. (2008). Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis 29: 568-572. http://dx.doi.org/10.1093/carcin/bgm253 PMid:17999989 DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188. http://dx.doi.org/10.1016/0197-2456(86)90046-2 Dossus L, Kaaks R, Canzian F, Albanes D, et al. (2010). PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31: 455-461. http://dx.doi.org/10.1093/carcin/bgp307 PMid:19965896 PMCid:2832545 Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. http://dx.doi.org/10.1136/bmj.315.7109.629 PMid:9310563 PMCid:2127453 Gupta S, Srivastava M, Ahmad N, Bostwick DG, et al. (2000). Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42: 73-78. http://dx.doi.org/10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G Hiatt RA, Armstrong MA, Klatsky AL and Sidney S (1994). Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control 5: 66-72. http://dx.doi.org/10.1007/BF01830728 PMid:7510134 Hori S, Butler E and McLoughlin J (2011). Prostate cancer and diet: food for thought? BJU Int. 107: 1348-1359. http://dx.doi.org/10.1111/j.1464-410X.2010.09897.x PMid:21518228 Ioannidis JP, Boffetta P, Little J, O'Brien TR, et al. (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol. 37: 120-132. http://dx.doi.org/10.1093/ije/dym159 PMid:17898028 Kirschenbaum A, Klausner AP, Lee R, Unger P, et al. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56: 671-676. http://dx.doi.org/10.1016/S0090-4295(00)00674-9 Kosaka T, Miyata A, Ihara H, Hara S, et al. (1994). Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem. 221: 889-897. http://dx.doi.org/10.1111/j.1432-1033.1994.tb18804.x PMid:8181472 Lee LM, Pan CC, Cheng CJ, Chi CW, et al. (2001). Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 21: 1291-1294. PMid:11396201 Liang Y, Liu JL, Wu Y, Zhang ZY, et al. (2011). Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J. Exp. Med. 223: 137-144. http://dx.doi.org/10.1620/tjem.223.137 PMid:21304218 Liu JL, Liang Y, Wang ZN, Zhou X, et al. (2010). Cyclooxygenase-2 polymorphisms and susceptibility to gastric carcinoma: a meta-analysis. World J. Gastroenterol. 16: 5510-5517. http://dx.doi.org/10.3748/wjg.v16.i43.5510 PMid:21086572 PMCid:2988247 Madaan S, Abel PD, Chaudhary KS, Hewitt R, et al. (2000). Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 86: 736-741. http://dx.doi.org/10.1046/j.1464-410x.2000.00867.x PMid:11069387 Mahmud S, Franco E and Aprikian A (2004). Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br. J. Cancer 90: 93-99. http://dx.doi.org/10.1038/sj.bjc.6601416 PMid:14710213 PMCid:2395299 Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22: 719-748. PMid:13655060 Masferrer JL, Leahy KM, Koki AT, Zweifel BS, et al. (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60: 1306-1311. PMid:10728691 McArdle PA, Mir K, Almushatat AS, Wallace AM, et al. (2006). Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 77: 127-129. http://dx.doi.org/10.1159/000093905 PMid:16888416 Murad A, Lewis SJ, Smith GD, Collin SM, et al. (2009). PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer Prostatic Dis. 12: 296-300. http://dx.doi.org/10.1038/pcan.2009.18 PMid:19488068 O'Byrne KJ and Dalgleish AG (2001). Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 85: 473-483. http://dx.doi.org/10.1054/bjoc.2001.1943 PMid:11506482 PMCid:2364095 Panguluri RC, Long LO, Chen W, Wang S, et al. (2004). COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966. http://dx.doi.org/10.1093/carcin/bgh100 PMid:14754878 Shacter E and Weitzman SA (2002). Chronic inflammation and cancer. Oncology 16: 217-26, 229. PMid:11866137 Shahedi K, Lindstrom S, Zheng SL, Wiklund F, et al. (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int. J. Cancer 119: 668-672. http://dx.doi.org/10.1002/ijc.21864 PMid:16506214 Tsujii M and DuBois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501. http://dx.doi.org/10.1016/0092-8674(95)90127-2 Uotila P, Valve E, Martikainen P, Nevalainen M, et al. (2001). Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res. 29: 23-28. http://dx.doi.org/10.1007/s002400000148 PMid:11310211 Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, et al. (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J. Surg. 33: 124-129. http://dx.doi.org/10.1007/s00268-008-9784-5 PMid:19011936 Wu HC, Chang CH, Ke HL, Chang WS, et al. (2011). Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res. 31: 221-225. PMid:21273602 Yoshimura R, Sano H, Masuda C, Kawamura M, et al. (2000). Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89: 589-596. http://dx.doi.org/10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C Yu KD, Chen AX, Yang C, Qiu LX, et al. (2010). Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 122: 251-257. http://dx.doi.org/10.1007/s10549-009-0688-3 PMid:20033767